Spots Global Cancer Trial Database for Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Official Title: A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.
Study ID: NCT04276597
Interventions
Study Description
Brief Summary: Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET. The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
Contact Details
Name: Ebrahim Delpassand, MD
Affiliation: Excel Diagnostics and Nuclear Oncology Center
Role: PRINCIPAL_INVESTIGATOR
Name: Rodolfo Nunez, MD
Affiliation: Excel Diagnostics and Nuclear Oncology Center
Role: STUDY_DIRECTOR
Name: Afshin Shafie, MD
Affiliation: Excel Diagnostics and Nuclear Oncology Center
Role: STUDY_DIRECTOR
Name: Ayman Gaber, MD
Affiliation: Excel Diagnostics and Nuclear Oncology Center
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
